Novo Nordisk Buys Heart Disease Drug Maker Cardior in $1.11 Billion Deal
Novo Nordisk AS (NVO), maker of the weight-loss drug Wegovy, is set to acquire Cardior Pharmaceuticals, a German drug company, in a deal for up to 1.025 billion euros ($1.11 billion).
Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market
Novo Nordisk is one of the leading drugmakers in the world, developing hit medications such as Ozempic. The company is using artificial intelligence (AI) to process larger volumes of data from clin...
Terry Smith's Fundsmith downgraded over recent mis-steps
Terry Smith's Fundsmith Equity, the UK's most popular fund, has been downgraded by Morningstar due to questions over the manager's recent portfolio moves. Fresh from the fund having underperformed...
Novo Nordisk targets heart disease in $1.1 billion deal
Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting cardiovascular disease.
Novo Nordisk to buy Cardior Pharmaceuticals for up to $1.1 bln
Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline.
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
Novo Nordisk sales face hit on slow US uptake of weight loss drug - analysts
Novo Nordisk (NYSE:NVO) is at risk of missing first-quarter consensus estimates, due in part to the slow uptake of its flagship Wegovy drug in the US, Jefferies analysts have warned. As per the ban...
Novo Nordisk's once-weekly basal insulin icodec recommended for marketing approval in Europe
Danish drugmaker Novo Nordisk on Thursday said its once-weekly basal insulin icodec for treatment of diabetes in adults had received a recommendation for marketing authorisation from the European M...
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
Novo Nordisk recently released trial results for its weight loss pill amycretin. In an early-stage trial, the drug performed better than Wegovy.
German health ministry says Ozempic exports are not a concern
Germany's health ministry said that no large volumes of diabetes drug Ozempic are being exported out of the country, quashing a suggestion by the nation's drugs regulator that outbound trade in the...
3 Top Stocks to Watch From the Best International Money Managers
#Morningstar #NovoNordisk #StockInvesting Managers of highly rated funds own these foreign stocks. Should you?
Novo Nordisk (NVO) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
Novo Nordisk is a leader and innovator in the diabetes drug market. The pharmaceutical company is making strides in obesity care, too.
Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
Novo Nordisk recently presented encouraging phase 1 results for an oral obesity treatment candidate. The company has many more promising programs in its early-stage pipeline.
Related Companies